Evidence map›Paper›PMID 40380262›Full record

SynthesisSystematic reviews2025

Optimal daratumumab-based regimen for patients with newly diagnosed and previously untreated multiple myeloma: systematic review and component network meta-analysis.

Xiaohua Huang, Jia Zhou, Yuxiao Qian, Jing He, Lu Yang, Zhigang Wang, Diu Wei, Mengjie Li, Wei Ma, Haiyan Lang

Abstract readNetwork Meta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Systematic reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaohua HuangHaematology Department, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.ORCID 0000-0002-7861-8041
Jia Zhou *The First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
Yuxiao Qian *The First Clinical Medicine College, Beijing University of Chinese Medicine, Beijing, China.
Jing HeHaematology Department, The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, China.
Lu YangHaematology Department, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Zhigang WangHaematology Department, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Diu WeiHaematology Department, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Mengjie LiHaematology Department, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Wei MaHaematology Department, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Haiyan LangHaematology Department, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China. julietlang@126.com.

Funding

Beijing University of Chinese Medicine zyyzdxk-2023268
6 · The paper itself

Abstract

backgroundDaratumumab (Dara)-based regimens have been investigated in randomized controlled trials (RCTs) involving patients with newly diagnosed and previously untreated multiple myeloma (NDMM), but the optimal daratumumab-based regimen remains unclear. This study compares the efficacy of daratumumab-containing regimens for NDMM patients and explores optimal combinations.

methodsDatabases were searched from inception until February 29, 2024. Trials comparing regimens with and without daratumumab, as well as their mutual comparisons, were included. Random effects models for serious adverse events (SAEs) and fixed effects models for other outcomes were utilized in both network meta-analysis (NMA) and component NMA (CNMA), with pooled effects estimated. The efficacy of all possible combinations of daratumumab with other drugs was assessed.

resultsA total of 17 trials were included, enrolling 7261 patients, of whom 2083 were treated with daratumumab. The optimal regimens for different outcomes were identified as follows: Dara-bortezomib (V)-melphalan (M)-corticosteroids (D) (Dara-VMD) showed the best results for both overall response rate (ORR) [RR = 1.97; 95% CI: 1.42 to 2.75; I

conclusionsDara-VRD, Dara-KRD, Dara-RD, and Dara-CRD are optimal daratumumab-based regimens for patients with newly diagnosed and previously untreated multiple myeloma.

Indexed as

Antibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsMultiple MyelomaBortezomibHumansRandomized Controlled Trials as TopicAntibodies, MonoclonalBortezomibdaratumumabComponent network meta-analysisDaratumumabLenalidomideMultiple myelomaNewly diagnosed

Identifiers

PMID40380262
PMCPMC12082950

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.